ASCT


Also found in: Acronyms.

autologous stem cell transplantation (ASCT)

a treatment for advanced or refractory solid tumors, such as neuroblastomas, lymphomas, and Ewing's sarcoma. Stem cells from the bone marrow or blood are withdrawn before high-dose irradiation or chemotherapy that destroys many of the remaining cells; afterwards the removed cells are reinfused to form a new population of blood cells.

ASCT

Abbreviation for:
allogeneic stem cell transplantation
American Society for Cytotechnology
Asylum Seeker Co-ordination Team (Medspeak-UK) 
autologous stem cell transplantation
References in periodicals archive ?
5] Nonstandard abbreviations: SPEP, serum protein electrophoresis; UPEP, urine protein electrophoresis; ASCT, autologous stem cell transplantation.
High-dose melphalan followed by ASCT is currently considered the most effective treatment for AL amyloidosis.
Although primary treatment with front-line combination chemotherapy can result in durable response rates, up to 30 percent of Hodgkin lymphoma and over 50 percent of systemic ALCL patients relapse or are refractory to front-line treatment and have few therapeutic options beyond ASCT.
2]) with ASCT is considered the standard of care for patients aged 65 years or older; however, intermediate-dose melphalan (100 mg/[m.
3] Nonstandard abbreviations: CML, chronic myeloid leukemia; RT-PCR, reverse transcription-PCR; CT, threshold cycle; ASCT, autologous stem cell transplantation; BMT, bone marrow transplantation; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; [alpha]-IFN, [alpha]-interferon; and HU, hydroxyurea.
An announcement is made by Takeda Oncology Company and Takeda Pharmaceutical Company Limited conditional marketing authorization for ADCETRIS for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Investigator Analysis Shows Median Overall Survival for ADCETRIS-Treated Relapsed HL Patients after ASCT Was 91 Months Compared with 28 Months among Non-ADCETRIS Patients-
Up to 30% of these patients relapse or are refractory to frontline treatment with only few patients having therapeutic options beyond ASCT.
Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for conditional approval of brentuximab vedotin for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
The vast majority of patients undergoing multiday-high dose chemotherapy and autologous stem cell transplantation still experience major acute and delayed chemotherapy-induced nausea and vomiting (CINV), showing how emesis control in the ASCT setting remains sub-optimal", said Dr.
Researchers shared the results on December 10, 2012, via an oral presentation entitled "Combination Immunotherapy After ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells.
ADCETRIS was granted accelerated approval by the FDA in August 2011 for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.